Display Settings:

Format

Send to:

Choose Destination
    Vaccine. 2009 Nov 5;27(47):6642-8. Epub 2009 Mar 25.

    Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.

    Source

    Baylor College of Medicine Vaccine Research Center, Houston, TX 77030, USA. wkeitel@bcm.edu

    Abstract

    Dosage-sparing strategies, adjuvants and alternative substrates for vaccine production are being explored for influenza vaccine development. We assessed the safety and immunogenicity of a Vero cell culture-grown inactivated whole virus influenza A/H5N1 vaccine with or without aluminum hydroxide adjuvant [Al(OH)(3)] in healthy young adults. Vaccines were well tolerated, but injection site discomfort was more frequent in groups receiving Al(OH)(3). Dose-related increases in serum antibody levels were observed. Neutralizing antibody titers varied significantly when tested by two different laboratories. Al(OH)(3) did not enhance HAI or neutralizing antibody responses, and contributed to increased injection site pain. Because influenza antibody titers vary significantly between different laboratories, international standardization of assays is warranted.

    PMID:
    19773098
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3022490
    Free PMC Article

    Images from this publication.See all images (5) Free text

    Figure 3
    Figure 5
    Figure 2
    Figure 4

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk